{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:28:28Z","timestamp":1757618908276,"version":"3.44.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The use of immune checkpoint inhibitor (ICI) therapy is increasing in pediatric oncology. ICIs can cause rheumatic-immune related adverse events (Rh-irAEs) such as inflammatory arthritis and myositis. Few case reports detail Rh-irAEs and their management in the pediatric population. Our objective was to assess the familiarity of pediatric rheumatologists (PRs) worldwide with Rh-irAEs, gauge confidence in managing these conditions, and identify knowledge gaps to guide future educational efforts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We circulated an online survey to 2084 PRs via the \u201cDr. Peter Dent Pediatric Rheumatology Bulletin Board.\u201d Responses were collected from June 2024 to September 2024. We collected data on practitioner demographics, knowledge of ICIs and Rh-irAEs, confidence in managing Rh-irAEs, and preferred educational resources.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixty-nine participants responded, of which 55 (80%) were PRs from academic centers. Despite global distribution, 56 (81%) responses came from North America. Thirty-four (49%) respondents were not aware of ICIs and their related mechanisms, indications, and side effects, and 40 (58%) were not familiar with irAEs. Fifty-five (80%) had never managed a patient with Rh-irAEs. Among those who had (14\/69, 21%), the median number of cases managed was 2.0 (IQR 0.0). Thirty-nine respondents were \u201cnot confident at all\u201d managing Rh-irAEs, 34 were \u201cnot confident at all\u201d managing pre-existing autoimmune diseases (PAD) in ICI users, and 46 were \u201cnot confident at all\u201d advising oncology colleagues on initiating or discontinuing ICIs in the context of Rh-irAEs or pre-existing autoimmune diseases (PAD). No respondents felt \u201ccompletely confident\u201d managing these conditions. Participants identified knowledge gaps in long-term management, acute management, and recognition and diagnosis. Forty-three indicated the need for pediatric-specific clinical guidelines. Of the 14 respondents with clinical experience treating Rh-irAEs, treatment varied, with 4 using nonsteroidal anti-inflammatory drugs, 3 using prednisone, and 4 combining prednisone with methotrexate. Long-term management also varied, with 5 using methotrexate, and 3 using tumor necrosis factor inhibitors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Significant knowledge gaps and a lack of confidence exist among PRs managing ICI-related Rh-irAEs. As ICI use increases in pediatric oncology, PRs\u2019 exposure to Rh-irAEs will follow. Targeted educational programs and clinical guidelines may be valuable to address these gaps.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12969-025-01127-x","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:47:13Z","timestamp":1752562033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-9377","authenticated-orcid":false,"given":"John","family":"Storwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Maltez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"6230","key":"1127_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"issue":"1","key":"1127_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","volume":"4","author":"LC Cappelli","year":"2020","unstructured":"Cappelli LC, Grieb SM, Shah AA, Bingham CO, Orbai A-M. Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps. BMC Rheumatol. 2020;4(1):32.","journal-title":"BMC Rheumatol"},{"key":"1127_CR3","doi-asserted-by":"crossref","unstructured":"Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015:76\u201383.","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"issue":"2","key":"1127_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3899\/jrheum.190084","volume":"47","author":"S Jamal","year":"2020","unstructured":"Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related adverse events associated with Cancer immunotherapy: A review for the practicing rheumatologist. J Rheumatol. 2020;47(2):166\u201375.","journal-title":"J Rheumatol"},{"issue":"1","key":"1127_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","volume":"80","author":"M Kostine","year":"2021","unstructured":"Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36\u201348.","journal-title":"Ann Rheum Dis"},{"key":"1127_CR6","doi-asserted-by":"publisher","first-page":"1182751","DOI":"10.3389\/fimmu.2023.1182751","volume":"14","author":"Y Hong","year":"2023","unstructured":"Hong Y, Song M, Lan Y, Wang J, Lu S, Zhang Y, et al. Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China. Front Immunol. 2023;14:1182751.","journal-title":"Front Immunol"},{"key":"1127_CR7","doi-asserted-by":"crossref","unstructured":"Ciurej A, Lewis E, Gupte A, Al-Antary E. Checkpoint immunotherapy in pediatric oncology: will we say checkmate soon?? Vaccines. (Basel). 2023;11(12).","DOI":"10.3390\/vaccines11121843"},{"issue":"8","key":"1127_CR8","doi-asserted-by":"publisher","first-page":"e7154","DOI":"10.1002\/cam4.7154","volume":"13","author":"A Gikandi","year":"2024","unstructured":"Gikandi A, Chi SN, Yeo KK, O\u2019Neill AF, Shulman DS, DuBois SG, et al. Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Med. 2024;13(8):e7154.","journal-title":"Cancer Med"},{"issue":"1","key":"1127_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-024-00983-3","volume":"22","author":"JA Storwick","year":"2024","unstructured":"Storwick JA, Tam H, Rosenbaum DG, Houghton K. Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to nivolumab and ipilimumab: a pediatric first. Pediatr Rheumatol Online J. 2024;22(1):49.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1127_CR10","unstructured":"Health UDo, Services H. Common terminology criteria for adverse events (CTCAE). (No Title). 2017."},{"key":"1127_CR11","first-page":"12","volume":"2","author":"N Maltez","year":"2019","unstructured":"Maltez N, Abdullah A, Fifi-Mah A, Hudson M, Jamal S. Checking in with immune checkpoint inhibitors: results of a needs assessment survey of Canadian rheumatologists. J Cancer Sci Th. 2019;2:12.","journal-title":"J Cancer Sci Th"},{"issue":"5","key":"1127_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3899\/jrheum.2023-0969","volume":"51","author":"A Rouhi","year":"2024","unstructured":"Rouhi A, Jamal S, Arreola LG, Moon D, Hudson M, Roberts J, et al. Immune checkpoint Inhibitor-Associated remitting seronegative symmetrical synovitis with pitting edema: description of a new entity by CanRIO. J Rheumatol. 2024;51(5):523\u20138.","journal-title":"J Rheumatol"},{"issue":"12","key":"1127_CR13","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1093\/rheumatology\/keab608","volume":"60","author":"K Lee","year":"2021","unstructured":"Lee K, Elahi S, Mashhouri S, Ye C. Gout presenting as a chronic inflammatory arthritis from immune checkpoint inhibitors: case series. Rheumatology (Oxford). 2021;60(12):e441\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1127_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/rheumatology\/keae099","volume":"64","author":"OCB Vermeulen","year":"2025","unstructured":"Vermeulen OCB, Brouwer E, Slart R, Sandovici M, Rutgers A, Hilterman TJ, et al. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology (Oxford). 2025;64(2):771\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1127_CR15","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","volume":"19","author":"J Roberts","year":"2020","unstructured":"Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. Autoimmun Rev. 2020;19(8):102595.","journal-title":"Autoimmun Rev"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01127-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:31:52Z","timestamp":1757241112000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01127-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1127"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01127-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"type":"electronic","value":"1546-0096"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Obtained through Ethics Review Board of The University of British Columbia (Ethics Approval #H23-03354).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"72"}}